Imagion Biosystems is pleased to report that we closed the first quarter of FY2021 maintaining a strong cash balance and having added a new study site for our Phase I HER2 Breast Cancer Study. You can read more about the status and progress of the study and other key achievements in the quarter in our latest Appendix 4C and Quarterly Activity Report.
The Unanswered Question in Prostate Cancer Diagnosis
September 24, 2026
Separating lethal disease from indolent disease remains the persistent difficulty, and molecular MRI may offer a way to see the difference. Prostate cancer is the